Type frequency and antimicrobial susceptibility of Mycobacterium avium-intracellulare complex strains isolated in Italy from AIDS and non-AIDS patients. 1996

L Fattorini, and V Vincent, and B Li, and Y Xiao, and A Varnerot, and E Tortoli, and C Piersimoni, and F Mandler, and M T Mascellino, and E Iona, and G Orefici
Laboratorio di Batteriologia e Micologia Medica. Istituto Superiore di Sanità, Roma, Italy.

Typing of the glycopeptidolipid antigens performed by thin layer chromatography on 59 Mycobacterium avium-intracellulare (MAC) strains isolated in Italy from AIDS patients showed that the most frequent types were 1, 4, 3, 8, and 21 (24, 19, 14, 14 and 8% of the strains, respectively). Among non-AIDS patients, types 1, 4 and 8 were also frequently found. The antimicrobial susceptibility tested in agar and/or liquid media to a panel of drugs indicated in clofazimine and rifabutin effective agents against both AIDS and non-AIDS strains. The data obtained show that MAC type distribution in Italy appears to be different from that reported for other countries. No major differences in drug susceptibility between AIDS and non-AIDS related strains were found.

UI MeSH Term Description Entries
D007558 Italy A country in southern Europe, a peninsula extending into the central Mediterranean Sea, northeast of Tunisia. The capital is Rome. Sardinia
D008297 Male Males
D008826 Microbial Sensitivity Tests Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses). Bacterial Sensitivity Tests,Drug Sensitivity Assay, Microbial,Minimum Inhibitory Concentration,Antibacterial Susceptibility Breakpoint Determination,Antibiogram,Antimicrobial Susceptibility Breakpoint Determination,Bacterial Sensitivity Test,Breakpoint Determination, Antibacterial Susceptibility,Breakpoint Determination, Antimicrobial Susceptibility,Fungal Drug Sensitivity Tests,Fungus Drug Sensitivity Tests,Sensitivity Test, Bacterial,Sensitivity Tests, Bacterial,Test, Bacterial Sensitivity,Tests, Bacterial Sensitivity,Viral Drug Sensitivity Tests,Virus Drug Sensitivity Tests,Antibiograms,Concentration, Minimum Inhibitory,Concentrations, Minimum Inhibitory,Inhibitory Concentration, Minimum,Inhibitory Concentrations, Minimum,Microbial Sensitivity Test,Minimum Inhibitory Concentrations,Sensitivity Test, Microbial,Sensitivity Tests, Microbial,Test, Microbial Sensitivity,Tests, Microbial Sensitivity
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002991 Clofazimine A fat-soluble riminophenazine dye used for the treatment of leprosy. It has been used investigationally in combination with other antimycobacterial drugs to treat Mycobacterium avium infections in AIDS patients. Clofazimine also has a marked anti-inflammatory effect and is given to control the leprosy reaction, erythema nodosum leprosum. (From AMA Drug Evaluations Annual, 1993, p1619) B-663,G-30,320,Lamprene,N,5-Bis(4-chlorophenyl)-3,5-dihydro-3-((1-methylethyl)imino)-2-phenazinamine,B 663,B663,G 30,320,G30,320
D005260 Female Females
D006678 HIV Human immunodeficiency virus. A non-taxonomic and historical term referring to any of two species, specifically HIV-1 and/or HIV-2. Prior to 1986, this was called human T-lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV). From 1986-1990, it was an official species called HIV. Since 1991, HIV was no longer considered an official species name; the two species were designated HIV-1 and HIV-2. AIDS Virus,HTLV-III,Human Immunodeficiency Viruses,Human T-Cell Lymphotropic Virus Type III,Human T-Lymphotropic Virus Type III,LAV-HTLV-III,Lymphadenopathy-Associated Virus,Acquired Immune Deficiency Syndrome Virus,Acquired Immunodeficiency Syndrome Virus,Human Immunodeficiency Virus,Human T Cell Lymphotropic Virus Type III,Human T Lymphotropic Virus Type III,Human T-Cell Leukemia Virus Type III,Immunodeficiency Virus, Human,Immunodeficiency Viruses, Human,Virus, Human Immunodeficiency,Viruses, Human Immunodeficiency,AIDS Viruses,Human T Cell Leukemia Virus Type III,Lymphadenopathy Associated Virus,Lymphadenopathy-Associated Viruses,Virus, AIDS,Virus, Lymphadenopathy-Associated,Viruses, AIDS,Viruses, Lymphadenopathy-Associated
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths

Related Publications

L Fattorini, and V Vincent, and B Li, and Y Xiao, and A Varnerot, and E Tortoli, and C Piersimoni, and F Mandler, and M T Mascellino, and E Iona, and G Orefici
April 1992, Zentralblatt fur Bakteriologie : international journal of medical microbiology,
L Fattorini, and V Vincent, and B Li, and Y Xiao, and A Varnerot, and E Tortoli, and C Piersimoni, and F Mandler, and M T Mascellino, and E Iona, and G Orefici
February 1994, Microbial pathogenesis,
L Fattorini, and V Vincent, and B Li, and Y Xiao, and A Varnerot, and E Tortoli, and C Piersimoni, and F Mandler, and M T Mascellino, and E Iona, and G Orefici
December 1991, Journal of chemotherapy (Florence, Italy),
L Fattorini, and V Vincent, and B Li, and Y Xiao, and A Varnerot, and E Tortoli, and C Piersimoni, and F Mandler, and M T Mascellino, and E Iona, and G Orefici
February 2000, Journal of applied microbiology,
L Fattorini, and V Vincent, and B Li, and Y Xiao, and A Varnerot, and E Tortoli, and C Piersimoni, and F Mandler, and M T Mascellino, and E Iona, and G Orefici
October 1993, Tubercle and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease,
L Fattorini, and V Vincent, and B Li, and Y Xiao, and A Varnerot, and E Tortoli, and C Piersimoni, and F Mandler, and M T Mascellino, and E Iona, and G Orefici
January 1978, Nordisk veterinaermedicin,
L Fattorini, and V Vincent, and B Li, and Y Xiao, and A Varnerot, and E Tortoli, and C Piersimoni, and F Mandler, and M T Mascellino, and E Iona, and G Orefici
November 1986, British medical journal (Clinical research ed.),
L Fattorini, and V Vincent, and B Li, and Y Xiao, and A Varnerot, and E Tortoli, and C Piersimoni, and F Mandler, and M T Mascellino, and E Iona, and G Orefici
April 2000, Journal of medical microbiology,
L Fattorini, and V Vincent, and B Li, and Y Xiao, and A Varnerot, and E Tortoli, and C Piersimoni, and F Mandler, and M T Mascellino, and E Iona, and G Orefici
September 1993, Antimicrobial agents and chemotherapy,
L Fattorini, and V Vincent, and B Li, and Y Xiao, and A Varnerot, and E Tortoli, and C Piersimoni, and F Mandler, and M T Mascellino, and E Iona, and G Orefici
November 1989, Lancet (London, England),
Copied contents to your clipboard!